Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Glofitamab Monotherapy and Combination Therapy in R/R Aggressive B-Cell Non-Hodgkin's Lymphoma
NCT06806033Phase 2Recruiting
- Sponsor
- Roche
- Start
- Mar 2025
- Primary completion
- Jan 2027
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 7
01
Overview
A Phase 2 trial of glofitamab in B-cell non-Hodgkin lymphoma, sponsored by Roche. Started Mar 2025; status: recruiting.
02
Drugs
glofitamab
03
Conditions
B-cell non-Hodgkin lymphoma
Beyond the preview
Go deeper on NCT06806033.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06806033.